Actionable news
All posts from Actionable news
Actionable news in JUNO: JUNO THERAPEUTICS Inc,

So I Was Right About Juno: So What?


Juno's clinical hold was lifted in an extremely rapid fashion by the FDA.

The reasons for this are manifold: high priority, clear lack of risk of death, major efficacy.

ALL remains a big bad monster of a rare leukemia (in adults), and Juno might be able to capitalize.

Over the course of less than a week, Juno Therapeutics (NASDAQ:JUNO) suffered one of the most (apparently) serious setbacks a clinical-stage biotech can see. Its trial was put on hold by the FDA over the deaths of 3 patients in the Phase 2 ROCKET trial, which will likely be a major study JUNO uses to seek approval.

Doom and gloom abounded. On the...